Capsaicin pretreatment increased the bioavailability of cyclosporin in rats: Involvement of P-glycoprotein and CYP 3A inhibition

Food and Chemical Toxicology

Volumn 62, Issue , 2013, Pages 323-328

  Zhai, Xue jia ^a   Shi, Fang ^a   Chen, Fen ^a   Lu, Yong ning ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Capsaicin; Cyclosporin; CYP3A; Food drug interactions; P glycoprotein

Indexed keywords

CAPSAICIN; CYCLOSPORIN A; CYTOCHROME P450 3A; CYTOCHROME P450 3A1; CYTOCHROME P450 3A2; DEXAMETHASONE; KETOCONAZOLE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; CYCLOSPORIN; CYP3A1 PROTEIN, RAT; CYP3A2 PROTEIN, RAT; MULTIDRUG RESISTANCE PROTEIN 3; P-GLYCOPROTEIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG RESPONSE; ENZYME INHIBITION; FOOD DRUG INTERACTION; INTESTINE; LIVER; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; BIOAVAILABILITY; BLOOD; DIETARY SUPPLEMENT; DOSE RESPONSE; GENETICS; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; BIOLOGICAL AVAILABILITY; CAPSAICIN; CYCLOSPORINE; CYTOCHROME P-450 CYP3A; DEXAMETHASONE; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FOOD-DRUG INTERACTIONS; KETOCONAZOLE; MALE; P-GLYCOPROTEIN; P-GLYCOPROTEINS; RATS, SPRAGUE-DAWLEY;

EID: 84884376237     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2013.08.068     Document Type: Article

References (28)

1. An D., Yao Z.Y., He G.Y. With fluoride medium - pepper in fluorine pollution status in Guizhou. End. Dis. Bull. 1996, 11:55-57.
2. Babbar S., Chanda S., Bley K. Inhibition and induction of human cytochrome P450 enzymes in vitro by capsaicin. Xenobiotica 2010, 40:807-816.
3. Belza A., Frandsen E., Kondrup J. Body fat loss achieved by stimulation of thermogenesis by a combination of bioactive food ingredients: a placebo-controlled, double-blind 8-week intervention in obese subjects. Int. J. Obes. (Lond.) 2007, 31:121-130.
4. Bode A.M., Dong Z. The two faces of capsaicin. Cancer Res. 2011, 71:2809-2814.
5. Buck S.H., Burks T.F. Capsaicin: hot new pharmacological tools. Trends Pharmacol. Sci. 1983, 4:84-87.
6. Burke J.F., Pirsch J.D., Ramos E.L., Salomon D.R., Stablein D.M., Van Buren D.H., West J.C. Long-term efficacy and safety of cyclosporine in renal-transplant recipients. N. Engl. J. Med. 1994, 331:358-363.
7. Chen X.W., Serag E.S., Sneed K.B., Zhou S.F. Herbal bioactivation, molecular targets and the toxicity relevance. Chem. Biol. Interact. 2011, 192:161-176.
8. Díaz-Laviada I. Effect of capsaicin on prostate cancer cells. Future Oncol. 2010, 6:1545-1550.
9. Gooding S.M., Canter P.H., Coelho H.F., Boddy K., Ernst E. Systematic review of topical capsaicin in the treatment of pruritus. Int. J. Dermatol. 2010, 49:858-865.
10. Hachiya S., Kawabata F., Ohnuki K., Inoue N., Yoneda H., Yazawa S., Fushiki T. Effects of CH-19 Sweet, a non-pungent cultivar of red pepper, on sympathetic nervous activity, body temperature, heart rate, and blood pressure in humans. Biosci. Biotechnol. Biochem. 2007, 71:671-676.
11. Hayman M., Kam P.C.A. Capsaicin: a review of its pharmacology and clinical applications. Curr. Anaesth. Crit. Care 2008, 19:338-343.
12. Hirotani Y., Yamamoto K., Tomishi H., Nishihori T., Umeda T., Tanaka K. Effects of capsaicin on the pharmacokinetics of digoxin, phenytoin, and theophylline in rats. Jpn. J. TDM 2007, 24:23-28.
13. Hou Y.C., Lin S.P., Chao P.D. Liquorice reduced cyclosporine bioavailability by activating P-glycoprotein and CYP 3A. Food Chem. 2012, 135:2307-2312.
14. Hsiao P., Unadkat J.D. P-glycoprotein-based loperamide-cyclosporine drug interaction at the rat blood-brain barrier: prediction from in vitro studies and extrapolation to humans. Mol. Pharm. 2012, 9:629-633.
15. Josse A.R., Sherriffs S.S., Holwerda A.M., Andrews R., Staples A.W., Phillips S.M. Effects of capsinoid ingestion on energy expenditure and lipid oxidation at rest and during exercise. Nutr. Metab. (Lond.) 2010, 7:65-74.
16. Kitahara K., Kawai S. Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis. Curr. Opin. Rheumatol. 2007, 19:238-245.
17. Lim K., Yoshioka M., Kikuzato S., Kiyonaga A., Tanaka H., Shindo M., Suzuki M. Dietary red pepper ingestion increases carbohydrate oxidation at rest and during exercise in runners. Med. Sci. Sports Exerc. 1997, 29:355-361.
18. Monsereenusorn Y., Kongsamut S., Pezalla P.D. Capsaicin-a literature survey. Crit. Rev. Toxicol. 1982, 10:321-339.
19. Oga E.F., Sekine S., Shitara Y., Horie T. Potential P-glycoprotein-mediated drug-drug interactions of antimalarial agents in Caco-2 cells. Am. J. Trop. Med. Hyg. 2012, 87:64-69.
20. Pawłowska M., Augustin E. Expression systems of cytochrome P450 proteins in studies of drug metabolism in vitro. Postepy Hig. Med. Dosw. 2011, 65:367-376.
21. Perucka I., Oleszek W. Extraction and determination of capsaicinoids in fruit of hot pepper Capsicum annuum L. by spectrophotometry and high-performance liquid chromatography. Food Chem. 2000, 71:287-291.
22. Reyes-Escogido M.L., Gonzalez-Mondragon E.G., Vazquez-Tzompantzi E. Chemical and pharmacological aspects of capsaicin. Molecules 2011, 16:1253-1270.
23. Takanohashi T., Isaka M., Ubukata K., Mihara R., Bernard B.K. Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int. J. Toxicol. 2010, 29:22S-26S.
24. Tsukura Y., Mori M., Hirotani Y., Ikeda K., Amano F., Kato R., Ijiri Y., Tanaka K. Effects of capsaicin on cellular damage and monolayer permeability in human intestinal Caco-2 cells. Biol. Pharm. Bull. 2007, 30:1982-1986.
25. Yu C.P., Wu P.P., Hou Y.C., Lin S.P., Tsai S.Y., Chen C.T., Chao P.D. Quercetin and rutin reduced the bioavailability of cyclosporine from Neoral, an immunosuppressant, through activating P-glycoprotein and CYP 3A4. J Agric. Food Chem. 2011, 59:4644-4648.
26. Yuan R., Madani S., Wei X.X., Reynolds K., Huang S.M. Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab. Dispos. 2002, 30:1311-1319.
27. Zhou S., Koh H.L., Gao Y., Gong Z.Y., Lee E.J. Herbal bioactivation: the good, the bad and the ugly. Life Sci. 2004, 74:935-968.
28. Zhou S.F., Xue C.C., Yu X.Q., Wang G. Metabolic activation of herbal and dietary constituents and its clinical and toxicological implications: an update. Curr. Drug Metab. 2007, 8:526-553.